Rituximab: enhancing stem cell transplantation in mantle cell lymphoma
- 1 February 2002
- journal article
- review article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 29 (S1) , S10-S13
- https://doi.org/10.1038/sj.bmt.1703296
Abstract
Mantle cell lymphoma (MCL) responds poorly to standard chemotherapy regimens used in non-Hodgkin's lymphoma. As a result, a combination of high-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) is being investigated in patients with MCL. So far, however, there is no evidence for long-term remission – believed, in part, to be due to contamination of the transfusion product with residual cancer cells. Many ex-vivo purging methods have been developed to remove tumour cells, but these are complicated, time-consuming and expensive. This study describes an in vivo purging method using rituximab to produce a tumour-free stem cell product for re-infusion following HDT. The regimen is split into a purging phase and a myeloablative phase, which together consist of four-step high-dose sequential chemotherapy (sHDT) and six infusions of rituximab immunotherapy. The sHDT comprises cyclophosphamide, cytosine arabinoside, melphalan and mitoxantrone plus melphalan. There are two separate stem cell harvests and three reinfusions. In a pilot study 28 patients with untreated MCL received standard chemotherapy followed by sHDT with rituximab in vivo purging. Preliminary results indicate that in PCR analyses of leukaphereses from 20 assessable patients, 100% lymphoma-negative harvests were achieved following in vivo purging. PCR analyses of the bone marrow following the four-step high-dose regimen with purging and transplantation showed that all patients achieved molecular remission. After a median follow-up of 22 months (range 10–42 months), two patients had died while 26 were alive and disease free. This method allows efficient in vivo purging in the context of an effective chemotherapy regimen and may have a role as first-line therapy in MCL patients who respond poorly to standard treatment. Bone Marrow Transplantation (2002) 29, Suppl. 1, S10–S13. doi:10.1038/sj.bmt.1703296Keywords
This publication has 13 references indexed in Scilit:
- The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997Histopathology, 2000
- Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissionsLeukemia, 1999
- Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.Journal of Clinical Oncology, 1998
- High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission.Journal of Clinical Oncology, 1998
- High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin’s lymphomas: a single center experience on 18 patientsBone Marrow Transplantation, 1998
- Lymphoma classification--the gap between biology and clinical management is closingBlood, 1996
- Haematological support of high-dose sequential chemotherapy: Clinical evidence for reduction of toxicity and high response rates in poor risk lymphomasAnnals of Oncology, 1995
- Cyclin D1 protein analysis in the diagnosis of mantle cell lymphomaBlood, 1995
- A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]Blood, 1994
- Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomasBlood, 1994